Skip to main content
SCPX
OTC Life Sciences

Scorpius Holdings Secures $239.5K in Highly Onerous Debt with Unfavorable Redemption Terms

Analysis by Wiseek.ai
Sentiment info
Negative
Importance info
9
Price
$0.001
Mkt Cap
$61.143K
52W Low
$0
52W High
$0.8
Market data snapshot near publication time

summarizeSummary

This financing is a critical event for Scorpius Holdings, highlighting severe financial distress. The company has taken on a substantial amount of debt relative to its size, under highly unfavorable terms. These include a 15% premium on principal repayment and a clause granting the noteholder the right to demand full redemption from any future financing proceeds. This structure suggests the company was in a very weak bargaining position, likely desperate for capital, and could face significant challenges in repaying these short-term obligations or securing less onerous financing in the future. Investors should view this as a strong negative signal regarding the company's financial health and its ability to sustain operations.


check_boxKey Events

  • New Debt Issuance

    Scorpius Holdings issued four non-convertible promissory notes totaling $239,539.77 to an institutional investor, 3i, L.P.

  • Onerous Repayment Terms

    The notes carry a 5.0% annual interest rate and require a 15% premium on the principal amount upon maturity or redemption, significantly increasing the effective cost of capital.

  • Short-Term Maturity

    All notes mature between June and July 2026, creating near-term repayment pressure for the company.

  • Future Financing Constraint

    The noteholder has the right to demand full redemption of the notes, including the premium, using up to 100% of the gross proceeds from any future company financing, potentially hindering subsequent capital raises.


auto_awesomeAnalysis

This financing is a critical event for Scorpius Holdings, highlighting severe financial distress. The company has taken on a substantial amount of debt relative to its size, under highly unfavorable terms. These include a 15% premium on principal repayment and a clause granting the noteholder the right to demand full redemption from any future financing proceeds. This structure suggests the company was in a very weak bargaining position, likely desperate for capital, and could face significant challenges in repaying these short-term obligations or securing less onerous financing in the future. Investors should view this as a strong negative signal regarding the company's financial health and its ability to sustain operations.

在该文件披露时,SCPX的交易价格为$0.00,交易所为OTC,所属行业为Life Sciences,市值约为$6.1万。 52周交易区间为$0.00至$0.80。 这份文件被评估为消极市场情绪,重要性评分为9/10。

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed SCPX - Latest Insights

SCPX
Apr 07, 2026, 5:43 PM EDT
Filing Type: 8-K
Importance Score:
8
SCPX
Mar 19, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
9
SCPX
Mar 10, 2026, 4:15 PM EDT
Filing Type: 8-K/A
Importance Score:
9
SCPX
Feb 17, 2026, 4:35 PM EST
Filing Type: 10-Q
Importance Score:
10
SCPX
Jan 29, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
10
SCPX
Jan 13, 2026, 4:57 PM EST
Filing Type: 8-K
Importance Score:
9
SCPX
Jan 12, 2026, 4:31 PM EST
Filing Type: 10-Q
Importance Score:
10